Sign in
Knowstox

Fundamentals snapshot

SELLAS Life Sciences Group, Inc.

SLS · NCM · Healthcare · Biotechnology

Current price

$9.98

52-week range

$1.39 - $15.88

Market cap

$2.02B

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-20.04x Concerning

Net cash $137.61M. Interest coverage shows how many times profit covers the interest bill.

What this company does

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group is a company developing new medicines, mainly for cancer. Their money comes from research and development partnerships with other big drug companies. This is important because these partnerships provide funding for their promising cancer treatments.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Revenue $0.00
Net income $-9.61M
Diluted EPS -0.05
Operating cash flow $-7.59M
Free cash flow —
Revenue —
Net income $-8.41M
Diluted EPS -0.05
Operating cash flow $-8.85M
Free cash flow —
Revenue —
Net income $-7.66M
Diluted EPS -0.05
Operating cash flow $-4.92M
Free cash flow —
Revenue —
Net income $-6.79M
Diluted EPS -0.06
Operating cash flow $-7.07M
Free cash flow —
Revenue $0.00
Net income $-6.60M
Diluted EPS -0.07
Operating cash flow $-7.33M
Free cash flow —
Revenue —
Net income $-5.81M
Diluted EPS -0.07
Operating cash flow $-9.07M
Free cash flow —
Revenue —
Net income $-6.74M
Diluted EPS -0.06
Operating cash flow $-7.15M
Free cash flow —
Revenue —
Net income $-7.11M
Diluted EPS -0.10
Operating cash flow $-7.81M
Free cash flow —

Is it cheap or expensive?

Fair value — vs current price $9.98

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $137.6M - more cash than debt. Interest coverage -20.0x.

Net debt $-137.61M
Interest coverage -20.04x

SELLAS Life Sciences Group, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.

Healthy
Worse cushion Baseline Better cushion
SLS BASELINE SELLAS Life Sciences Group, Inc.

Total debt $737.00K Interest coverage -20.04x This is the baseline the peer rows are being compared against.

-20.04x

What you should know

The case for and against SLS

0 Rewards 1 Risk

Rewards

Risks

  • Return on equity was -39.6% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-99.80x
P/B
14.63x
P/S
—
EV/EBITDA
—
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-39.6%
ROA
-23.3%

Health

Liquidity and balance-sheet strength

Debt / equity
0.01x
Current ratio
18.83x
Quick ratio
18.28x
Total debt
$737.00K
Total cash
$138.34M

Growth

How the business has been compounding

Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.21
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-28.42M
Free CF TTM
$-28.39M
FCF margin
—

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—